Trial Profile

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bintrafusp alfa (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Pemetrexed (Primary) ; Durvalumab; Paclitaxel
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors EMD Serono Research & Development Institute

03 Oct 2023 Results published in the Journal of Thoracic Oncology
21 Jul 2023 This trial has been completed in Germany (End Date: 17 Feb 2023), according to European Clinical Trials Database record.
16 Jul 2023 This trial has been completed in Netherlands (End Date: 17 Feb 2023), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com